Clinical Trials Logo

Clinical Trial Summary

ET is the final stage of IVF which independently influences the treatment outcome. Successful embryo implantation is dependent on uterine receptivity. Atosiban is a novel class of drug which is effective in priming the uterus for implantation. It reduces uterine contractions and increases endomyometrial perfusion, both of which have potential benefits regarding improved IRs, CPR, and ongoing pregnancy rates. Atosiban has a good embryonic safety profile. It has no systemic toxicity, no mutagenic effects, and no carcinogenic effects


Clinical Trial Description

ET is a critical step of an IVF cycle that merits the utmost attention. Its success depends on the frequency of uterine contractions, the endometrial receptivity and the quality of embryos transferred. Uterine contractions are the most fundamental constituents of the uterine receptivity. Excessive contractions may decrease the implantation potential of embryos by expelling the embryos from the uterus. Studies have revealed a six-fold increase in uterine contractility in IVF cycles when measured before ET as compared to the condition before ovulation in natural cycles. Excessive manipulation of the cervix such as the use of tenaculum during difficult ET can also trigger uterine contractions, consequently leading to failure of embryo implantation. IVF success rates have been potentially improved by the use of drugs that inhibit pronounced uterine contractions at the time of ET. Treatment strategies such as the use of beta-agonists or nonsteroidal anti-inflammatory agents for tocolysis have not been beneficial in IVF-ET procedures. Atosiban is a combined oxytocin/vasopressin V1A antagonist. It functions mainly by blocking oxytocin and vasopressin V1a receptors to decrease the frequency and amplitude of uterine contractions, which enhances implantation and pregnancy rates. RIF remains unexplained in most cases, which results in considerable variation in how RIF is treated and managed. Atosiban competes with oxytocin at oxytocin receptors in endometrial cells and inhibits oxytocin-induced PGF2α release, thus inhibiting uterine contractions and increasing chances of embryo implantation and may add value in improving the outcome in RIF patients. Recently published studies showed that atosiban inhibits oxytocin-induced PGF2α and uterine contractility, consequently leading to improved IRs. Studies have shown a considerable reduction in the frequency of uterine contractions before and after the administration of atosiban in women undergoing ET. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04118959
Study type Observational
Source Al Baraka Fertility Hospital
Contact Kamal eldin Rageh, M.D.
Phone 0097333153871
Email dr_kamal_rageh@yahoo.com
Status Recruiting
Phase
Start date October 10, 2019
Completion date November 25, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03660735 - The PIP Study - Pre- IVF Immune Profiling Study
Not yet recruiting NCT04528277 - Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis Phase 3
Recruiting NCT04998279 - Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women With History of RIF
Completed NCT03267797 - hCG-activated PBMC-therapy in RIF Patients N/A
Recruiting NCT05343572 - Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium Early Phase 1
Not yet recruiting NCT02752568 - Assisted Hatching Versus Endometrial Scratch in Recurrent Implantation Failure N/A
Recruiting NCT04822207 - Effect of Acupuncture on the Clinical Outcome of IVF-ET in Patients With Recurrent Implantation Failure N/A
Recruiting NCT03900780 - Preimplantation Genetic Testing for Aneuploidies in Patients With Recurrent Implantation Failure N/A
Not yet recruiting NCT03549728 - Effect of Granulocyte Colony-stimulating Factor on Clinical Pregnancy Rate in Patients With Endometriosis Phase 2
Completed NCT03174964 - Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Phase 2
Completed NCT03161340 - Immunomodulatory Effects of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation Failure Phase 2
Not yet recruiting NCT01278706 - Endometrial Biopsy Protocol for In Vitro Fertilization (IVF) N/A
Completed NCT00750451 - Low Molecular Weight Heparin in Recurrent Implantation Failure N/A
Not yet recruiting NCT03690830 - Use of Metabolomics for the Identification of Endometrial Biomarkers for IRPL and RIF After in Vitro Fertilization N/A
Not yet recruiting NCT03355937 - Using Microfluidic Separation Sperm Selection for Unexplained Infertility and Reccurrent Implantation Failure N/A
Recruiting NCT05169541 - Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction
Completed NCT04085783 - PRP in Recurrent Implantation Failure N/A
Not yet recruiting NCT03365466 - Anticoagulation Therapies Effect on the Endometrial Blood Flow and Pregnancy Outcomes in Unexplained Recurrent Implantation Failure Women N/A
Active, not recruiting NCT03421639 - Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis Phase 4
Recruiting NCT04293068 - Effect of Reproductive Tract Microbiota on Pregnancy Outcome in IVF/ICSI